Press release
MedVi Unveils Its Cheaper Compounded GLP-1 Weight Management Medication Alternative
Affordable telehealth platform offers cost-saving GLP-1 medication options for Americans seeking to manage weight without breaking the bank-physician-supervised care starting at just $179 per month.Image: https://www.abnewswire.com/upload/2025/10/58a28bbefc869a8ec591ab5122e76187.jpg
United States - As brand-name GLP-1 medications like Wegovy and Ozempic continue to carry monthly costs exceeding $1,000 without insurance, MedVi today released a comprehensive overview of cheaper, compounded alternatives available to American patients. With over 500,000 patients served, MedVi addresses the critical question: Which compounded GLP-1 medications are more affordable alternatives in the United States?
The answer includes multiple affordable options-and MedVi provides physician-supervised access to all of them starting at just $179 per month.
Three Primary Cheaper Compounded GLP-1 Alternatives
*
Compounded Semaglutide - Same active ingredient as Wegovy and Ozempic. Available in both weekly injection and daily oral formats, offering comparable results at a fraction of the cost.
*
Compounded Liraglutide - Daily injection alternative, with a proven safety track record and reliable appetite control.
*
Compounded Tirzepatide - Dual GLP-1/GIP receptor agonist delivering enhanced weight loss, with average results of 20%+ reduction in body weight in clinical studies.
Dramatic Cost Savings
Brand-Name Monthly Costs (Without Insurance):
*
Wegovy: $1,349-$1,850
*
Ozempic: $936-$998
*
Saxenda: $1,435-$1,600
*
Zepbound: $1,400-$1,600
*
Mounjaro: $1,023-$1,400
MedVi Compounded Alternatives:
*
Semaglutide Injections/Tablets: $179/month
*
Liraglutide Injections: $179/month
*
Tirzepatide Oral: $249/month
*
Tirzepatide Injections: $279/month
Savings range from 70% to 90% below brand-name pricing, with all-inclusive physician care.
Why Compounded Medications Cost Less
*
Prepared by licensed compounding pharmacies instead of major pharmaceutical companies.
*
Cash-based pricing with no insurance delays or prior authorization denials.
*
Telehealth delivery reduces overhead while maintaining complete physician oversight and control.
MedVi's Comprehensive Program
*
Multiple GLP-1 options are prescribed based on a patient's medical history and treatment goals.
*
Choice of weekly GLP injections [https://www.buzzfeed.com/medvisemaglutide], daily injections, tablets, lozenges, or oral drops.
*
Physician-supervised titration to minimize side effects.
*
Transparent all-inclusive pricing (consultation, medication, supplies, monitoring, shipping).
*
Ongoing unlimited provider access and support.
Clinical Effectiveness
*
Semaglutide: 15-20% body weight loss in 68 weeks.
*
Liraglutide: 8-12% body weight loss in 56 weeks.
*
Tirzepatide: 20-25% body weight loss in 72 weeks, with enhanced metabolic improvements.
Safety & Oversight
*
All medications are prepared in FDA-regulated compounding facilities.
*
Prescriptions only after licensed US-physician evaluation (via OpenLoop Health).
*
Comprehensive patient screening, monitoring, and education provided.
Patient Testimonials
*
Chris lost 88 lbs: "GLP-1 medication saved my life. Thank you."
*
Melissa lost 119 lbs: "After my metabolic reset, the weight vanished."
*
Greg lost 70 lbs: "Dieting days are over."
Competitor Comparison
*
MedVi: $179-$279/month, no fees, multiple options, unlimited provider access.
*
Henry Meds: $179-$297/month, additional fees may apply.
*
Shed Rx: $249-$299/month, requires prepayment.
*
Defy Medical: $265-$649/month, consultation/labs extra.
*
Invigor: $320-$420/month, subscription model.
Special Offer
Fall Promotion: $120 in savings plus free expedited shipping on all compounded options.
To learn more, visit https://medvi.io
About MedVi
MedVi is a nationwide telehealth platform providing affordable, physician-supervised GLP-1 weight loss programs. Partnering with OpenLoop Health and FDA-regulated pharmacies, MedVi ensures high standards of care while delivering compounded semaglutide, liraglutide, and tirzepatide at transparent, all-inclusive prices starting at $179/month.
With more than 500,000 patients served, MedVi's mission is to make effective weight loss treatments accessible to all Americans, regardless of insurance coverage.
For media inquiries, interviews, or additional information email help@medvi.io or call (323) 690-1561.
Media Contact
Company Name: MedVi Wellness
Contact Person: Media Relations
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=medvi-unveils-its-cheaper-compounded-glp1-weight-management-medication-alternative]
Phone: (323) 690-1561
City: Newark
State: DE
Country: United States
Website: http://medvi.io
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release MedVi Unveils Its Cheaper Compounded GLP-1 Weight Management Medication Alternative here
News-ID: 4206127 • Views: …
More Releases from ABNewswire
Genloop Meets Prime Minister Narendra Modi to Advance Vision for Ethical, Scalab …
Genloop leaders met with India's Prime Minister to discuss advancing ethical, scalable AI from innovation to real-world deployment.
Santa Monica, CA - January 14, 2026 - Genloop [https://genloop.ai/?utm_source=ABNews&utm_medium=email&utm_campaign=1752vc], a portfolio company of 1752vc [http://1752.vc/?utm_source=abnews] (formerly Pegasus Angel Accelerator), announced that its leadership met with the Prime Minister of India, Narendra Modi, at his official residence, 7 Lok Kalyan Marg, for a high-level strategic discussion on the future of artificial intelligence in…
Alopecia Areata Market to Witness Promising Upswing by 2034, DelveInsight Foreca …
The Key Alopecia Areata Companies in the market include - Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others.
The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage…
Neko Case Neon Grey Midnight Green 2026: Affordable Tickets + CITY10 Code for In …
Neko Case's Neon Grey Midnight Green Tour rocks North America in 2026, celebrating her acclaimed Sept 2025 album-first new solo work since 2018-with raw, live-recorded tracks, powerful vocals, and hits like "Hold On, Hold On." Catch her with Des Demonas (East/Midwest) or Destroyer (West) from Jan 8 Montreal to March dates in CO, CA & more!
Neko Case [https://www.capitalcitytickets.com/Neko-Case-Tickets] is embarking on her electrifying Neon Grey Midnight Green Tour in 2026,…
Toogood Gold Expands Footprint, Positioned for High-Impact Growth 2026 Alongside …
Toogood Gold Corp. (TSXV: TGC | OTCQB: TGGCF) reported final drilling assays from its 100%-owned Toogood Gold Project in Newfoundland, delivering results that significantly expand the scale, continuity, and upside potential of its gold discovery heading into 2026.
The Company's 2025 drill program confirmed the Quinlan target as a large, coherent gold system, with gold intersected in all 30 drill holes completed to date. High-grade intervals and visible gold were reported…
More Releases for MedVi
MEDVi Expands Access to Semaglutide Online With Updated Program Trusted by 100,0 …
MEDVi, a telehealth platform serving more than 100,000 patients, today announced continued nationwide momentum as Americans seek more convenient, clinician-supervised access to GLP-1 weight-loss medications, including semaglutide, through an all-inclusive online program designed to reduce friction, improve support, and set a higher bar for patient experience.
Disclosure: This announcement is for informational purposes only and does not constitute medical advice. Compounded semaglutide is not FDA-approved. This release may include links or…
My Start GLP 1 Reviews: The GLP 1 That is Changing the Way America loss Weight
In the modern era of health innovation, few breakthroughs have generated as much excitement as My Start GLP 1. In 2025, it has rapidly become one of the most talked-about doctor-supervised weight loss programs in the United States. With thousands of verified patient success stories, My Start GLP 1 has positioned itself as more than a trend-it is a science-backed revolution changing how we understand metabolism, hunger, and sustainable fat…
MedVi Expands Access to GLP-1 Medication - Compounded Semaglutide for Healthy Li …
The GLP-1 medication program by MedVi is now available nationwide starting at $179.
NEWARK, DE - MedVi Wellness, a leading telehealth provider in medical weight management, has announced the launch of its nationwide GLP-1 medication program, providing compounded semaglutide in both injectable and oral forms. Starting at $179 per month with no insurance required, MedVi [https://medvi.io] offers an affordable, physician-guided alternative to high-cost brand-name drugs such as Wegovy Registered and Ozempic…
MEDVi Personalized GLP-1 Medication Review - Is This the Future of Weight Loss a …
MEDVi Personalized GLP-1 Medication Review - Is This the Future of Weight Loss and Diabetes Management?
Introduction: Why Everyone's Talking About Personalized GLP-1 Medications
In today's fast-moving world of health innovation, one major trend is dominating Google searches and health forums alike-personalized GLP-1 medications. With the rise of obesity, prediabetes, and insulin resistance across all age groups, more people than ever are looking for smarter, science-backed solutions that deliver real results without…
MEDVi Revolutionizes Fitness Goals with Affordable, Doctor-Prescribed GLP-1 Medi …
Newark, Delaware - MEDVi, a leading provider of doctor-prescribed weight loss solutions, is making cutting-edge GLP-1 treatments accessible to millions across the United States. With medications like Semaglutide and Tirzepatide available for as low as $179 per month without insurance, MEDVi is transforming the weight loss industry by offering affordable, science-backed solutions.
With over 500,000 patients benefiting from its personalized programs, MEDVi provides individuals with a practical, medically supervised approach to…
